Literature DB >> 28462903

Long-term outcomes after TAVI in patients with different types of aortic stenosis: the conundrum of low flow, low gradient and low ejection fraction.

Miriam Puls1, Kerstin Pia Korte, Annalen Bleckmann, Mark Huenlich, Bernhard C Danner, Friedrich Schoendube, Gerd Hasenfuß, Claudius Jacobshagen, Wolfgang Schillinger.   

Abstract

AIMS: The objective of this study was to examine the impact of guideline-defined subtypes of severe aortic stenosis (AS) on long-term outcomes after TAVI. METHODS AND
RESULTS: Four hundred (400) consecutive patients who underwent TAVI (203 transapical, 197 transfemoral) at our institution 8/2008-3/2013 were followed systematically (for up to seven years). One hundred and forty-seven (147) individuals suffered from NEF-HG AS (LV-EF ≥50%, high Pmean ≥40 mmHg), 63 from LEF-HG AS (LV-EF <50%, high gradient), 77 from PLF-LG AS (LV-EF ≥50%, low gradient, stroke volume index [SVI] <35 ml/m²), and 81 from LEF-LG AS (LV-EF <50%, low gradient). LEF-LG status was associated with the highest all-cause and cardiovascular mortality and MACCE rate, whereas NEF-HG patients exhibited the best outcome (i.e., median survival 5.1 years in NEF-HG vs. 1.3 years in LEF-LG, p=0.0006; or vs. 3.3 years in PLF-LG, p=0.02). In multivariate analysis, LEF-LG status emerged as the outcome predictor with the highest hazard ratio for all-cause mortality (HR 2.86, p=0.003), cardiovascular mortality (HR 6.53, p<0.0001), and MACCE (HR 2.44, p=0.007), whereas neither baseline EF nor SVI <35 ml/m² independently predicted these endpoints.
CONCLUSIONS: These findings suggest that an assessment of LV-EF alone for outcome prediction after TAVI is inadequate; it is the guideline-defined subtype of AS that determines outcome.

Entities:  

Mesh:

Year:  2017        PMID: 28462903     DOI: 10.4244/EIJ-D-16-00801

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  4 in total

1.  Paradoxical low-flow aortic stenosis - baseline characteristics, impact on mortality.

Authors:  Karol Zbroński; Zenon Huczek; Monika Gawalko; Agata Ćwiek; Bartosz Rymuza; Kajetan Grodecki; Piotr Scisło; Radosław Wilimski; Janusz Kochman; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-04-04       Impact factor: 1.426

2.  Outcome of patients with heart failure after transcatheter aortic valve implantation.

Authors:  Ulrich Fischer-Rasokat; Matthias Renker; Christoph Liebetrau; Maren Weferling; Andreas Rolf; Mirko Doss; Helge Möllmann; Thomas Walther; Christian W Hamm; Won-Keun Kim
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

3.  Risk prediction in patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction undergoing TAVI.

Authors:  Sebastian Ludwig; Alina Goßling; Moritz Seiffert; Dirk Westermann; Jan-Malte Sinning; Atsushi Sugiura; Matti Adam; Victor Mauri; Derk Frank; Hatim Seoudy; Tanja Rudolph; Max Potratz; Lenard Conradi; Niklas Schofer
Journal:  Open Heart       Date:  2022-01

4.  Prognostic value of the H2 FPEF score in patients undergoing transcatheter aortic valve implantation.

Authors:  Sebastian Ludwig; Costanza Pellegrini; Alina Gossling; Tobias Rheude; Lisa Voigtländer; Oliver D Bhadra; Matthias Linder; Daniel Kalbacher; Benedikt Koell; Lara Waldschmidt; Johannes Schirmer; Moritz Seiffert; Hermann Reichenspurner; Stefan Blankenberg; Dirk Westermann; Lenard Conradi; Michael Joner; Niklas Schofer
Journal:  ESC Heart Fail       Date:  2020-11-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.